About
Base Editing Therapies
Areas of Focus
Categories
China
Team (2)
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
61
By Phase
EARLY_PHASE1: 5PHASE1: 1
By Status
ENROLLING_BY_INVITATION: 3RECRUITING: 2ACTIVE_NOT_RECRUITING: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
Today
Hover over trial bars to see details
Recent Trials
NCT07176923Lead Sponsor
CS-121 APOC3 Base Editing in FCS
EARLY_PHASE1Not yet recruiting
15 participants
Started: Sep 30, 2025 · Completed: Dec 31, 2026
NCT06717932Lead Sponsor
A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
N/AEnrolling by invitation
8 participants
Started: May 31, 2025 · Completed: Nov 30, 2039
NCT06685536Lead Sponsor
A Long-term Follow-up Study in Participants Who Received CS-101
N/AEnrolling by invitation
5 participants
Started: Jan 18, 2025 · Completed: Jul 31, 2039
NCT06565026Lead Sponsor
CS-206 in Patients With Sickle Cell Disease
EARLY_PHASE1Recruiting
5 participants
Started: Sep 2, 2024 · Completed: Jun 30, 2027
NCT06291961Lead Sponsor
A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
PHASE1Recruiting
8 participants
Started: Apr 18, 2024 · Completed: Jul 31, 2025
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...